These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 28035516)

  • 21. [Characteristics and diagnostic applications of circulating cell-free DNA in colorectal cancer].
    Barták BK; Márkus E; Kalmár A; Galamb O; Szigeti K; Nagy ZB; Zsigrai S; Tulassay Z; Dank M; Igaz P; Molnár B
    Orv Hetil; 2019 Jul; 160(30):1167-1177. PubMed ID: 31327245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
    Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D
    Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of Methylated SEPT9 in Korean Colorectal Cancer Patients: Comparison with Previous Studies.
    Kim H; Lee JK; Hong YJ; Moon SM; Shin US; Kwon H; Shin K; Chang YH
    Clin Lab; 2018 Sep; 64(9):1573-1579. PubMed ID: 30273999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Postoperative serum methylation levels of TAC1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer.
    Tham C; Chew M; Soong R; Lim J; Ang M; Tang C; Zhao Y; Ong SY; Liu Y
    Cancer; 2014 Oct; 120(20):3131-41. PubMed ID: 24925595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer.
    Barault L; Amatu A; Siravegna G; Ponzetti A; Moran S; Cassingena A; Mussolin B; Falcomatà C; Binder AM; Cristiano C; Oddo D; Guarrera S; Cancelliere C; Bustreo S; Bencardino K; Maden S; Vanzati A; Zavattari P; Matullo G; Truini M; Grady WM; Racca P; Michels KB; Siena S; Esteller M; Bardelli A; Sartore-Bianchi A; Di Nicolantonio F
    Gut; 2018 Nov; 67(11):1995-2005. PubMed ID: 28982739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel cell-free DNA methylation-based model improves the early detection of colorectal cancer.
    Wu X; Zhang Y; Hu T; He X; Zou Y; Deng Q; Ke J; Lian L; He X; Zhao D; Cai X; Chen Z; Wu X; Fan JB; Gao F; Lan P
    Mol Oncol; 2021 Oct; 15(10):2702-2714. PubMed ID: 33694305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum methylation levels of TAC1. SEPT9 and EYA4 as diagnostic markers for early colorectal cancers: a pilot study.
    Liu Y; Tham CK; Ong SY; Ho KS; Lim JF; Chew MH; Lim CK; Zhao Y; Tang CL; Eu KW
    Biomarkers; 2013 Aug; 18(5):399-405. PubMed ID: 23862763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancer.
    Danese E; Minicozzi AM; Benati M; Montagnana M; Paviati E; Salvagno GL; Lima-Oliveira G; Gusella M; Pasini F; Lippi G; Guidi GC
    PLoS One; 2015; 10(5):e0126417. PubMed ID: 25946211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
    Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
    Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients.
    Yang X; Xu ZJ; Chen X; Zeng SS; Qian L; Wei J; Peng M; Wang X; Liu WL; Ma HY; Gong ZC; Yan YL
    World J Gastroenterol; 2019 May; 25(17):2099-2109. PubMed ID: 31114136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.
    Tänzer M; Balluff B; Distler J; Hale K; Leodolter A; Röcken C; Molnar B; Schmid R; Lofton-Day C; Schuster T; Ebert MP
    PLoS One; 2010 Feb; 5(2):e9061. PubMed ID: 20140221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing.
    Li J; Zhou X; Liu X; Ren J; Wang J; Wang W; Zheng Y; Shi X; Sun T; Li Z; Kang A; Tang F; Wen L; Fu W
    Clin Chem; 2019 Jul; 65(7):916-926. PubMed ID: 31010820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis of DNA methylation alterations in cellfree DNA fraction during colorectal cancer development].
    Molnár KB
    Magy Onkol; 2020 Mar; 64(1):70-72. PubMed ID: 32181765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylome profiling identifies TCHH methylation in CfDNA as a noninvasive marker of liver metastasis in colorectal cancer.
    Chen S; Liu T; Bu D; Zhu J; Wang X; Pan Y; Liu Y; Lu ZJ; Wang P
    FASEB J; 2021 Jul; 35(7):e21720. PubMed ID: 34110642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colorectal cancer screening with blood-based biomarkers: cost-effectiveness of methylated septin 9 DNA versus current strategies.
    Ladabaum U; Allen J; Wandell M; Ramsey S
    Cancer Epidemiol Biomarkers Prev; 2013 Sep; 22(9):1567-76. PubMed ID: 23796793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A First Step to a Biomarker of Curative Surgery in Colorectal Cancer by Liquid Biopsy of Methylated Septin 9 Gene.
    Leon Arellano M; García-Arranz M; Ruiz R; Olivera R; Magallares S; Olmedillas-Lopez S; Valdes-Sanchez T; Guadalajara H; García-Olmo D
    Dis Markers; 2020; 2020():9761406. PubMed ID: 32566042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood.
    Payne SR
    Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.
    Jin P; Kang Q; Wang X; Yang L; Yu Y; Li N; He YQ; Han X; Hang J; Zhang J; Song L; Han Y; Sheng JQ
    J Gastroenterol Hepatol; 2015 May; 30(5):830-3. PubMed ID: 25471329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery and validation of methylation signatures in blood-based circulating tumor cell-free DNA in early detection of colorectal carcinoma: a case-control study.
    Sui J; Wu X; Wang C; Wang G; Li C; Zhao J; Zhang Y; Xiang J; Xu Y; Nian W; Cao F; Yu G; Lou Z; Hao L; Liu L; Li B; Zhang Z; Cai S; Liu H; Lan P; Zhang W
    Clin Epigenetics; 2021 Feb; 13(1):26. PubMed ID: 33536049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
    Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.